title: ACS chemical neuroscience molecule spotlight on viibryd (Vilazodone).
abstract: On January 21, 2011, the U.S. Food and Drug Administration approved Viibryd, a new selective serotonin reuptake inhibitor (SSRI), to treat major depressive disorder in adults developed by Clinical Data, Inc.
authors.affiliation: Department of Pharmacology and Chemistry and Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center,  Vanderbilt University , Nashville, Tennessee 37232-6600, United States.
authors.forename: Corey R
authors.initials: CR
authors.lastname: Hopkins
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001572:Benzofurans / Q000009:adverse effects / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy / Q000523:psychology; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D016032:Randomized Controlled Trials as Topic; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000069503:Vilazodone Hydrochloride; D055815:Young Adult
chemical_list: D000928:Antidepressive Agents; D001572:Benzofurans; D007211:Indoles; D010879:Piperazines; D017367:Selective Serotonin Reuptake Inhibitors; D000069503:Vilazodone Hydrochloride